Poster for last presentation now on the website.
https://alteritytherapeutics.com/wp-content/uploads/the-science/mds2025_stamler-201.pdf
Main difference from earlier analysis is increased treatment effect for the 75mg cohort in the 201 study, adjusting for the disproportionate number of individuals with severe orthostatic hypertension in the 75mg group. This is now 35% in lieu of the 30% previously reported.
- Forums
- ASX - By Stock
- ATH
- Ann: Alterity Presents Positive ATH434 Data at 2025 MDS Congress
ATH
alterity therapeutics limited
Add to My Watchlist
0.00%
!
0.9¢
Ann: Alterity Presents Positive ATH434 Data at 2025 MDS Congress, page-3
-
-
Top Stories
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.